Ageing demographics
A larger older population changes the balance between working-age participation, care needs, and the systems that support both.
A research agenda
Biological age and the economics of ageing
What better evidence could make answerable — without treating a research measure as a policy prescription.
01 — The problem
Chronological age describes a population. It does not describe its functional variation.
Two people of the same chronological age can have materially different physiological states. That variation matters to healthy life, working life, care demand, and the economics surrounding each.
Age-skewed healthcare use
Healthcare expenditure rises with age and is concentrated around periods of declining function and increasing morbidity.
The healthspan gap
Longer lives do not automatically mean more years in good health. The gap creates costs for individuals, families, employers, and public systems.
02 — Consequences
The costs are distributed across systems.
Productivity and participation
Declining health can reduce participation before chronological retirement thresholds, while caregiving responsibilities affect others in the workforce.
Budget pressure
Healthcare and long-term-care systems must respond to demand under demographic assumptions that continue to shift.
Evaluation at scale
Prevention programmes need outcome measures that can be read inside a policy cycle if resources are to follow evidence rather than aspiration.
03 — Where evidence would help
An evidence problem before a policy problem
Population health is described in age bands, cohorts, and life expectancy. These are administratively useful and biologically coarse.
The harder gap is that few healthy-ageing interventions have been tested with endpoints readable inside a policy cycle. Without that evidence, prevention policy rests on assumptions. BioAge Connect does not make policy recommendations; it runs intervention studies that could generate evidence for the questions below.
Health economics
Could longitudinal biological-age outcomes help evaluate the cost and durability of prevention programmes before long-term morbidity endpoints mature?
Policy evaluation
Could standardised measures support comparison across intervention sites while preserving appropriate uncertainty and population calibration?
Individual engagement
Could research feedback improve adherence to prevention programmes without turning a monitoring measure into a diagnosis or a condition of access?
Institutional design
What validation, safeguards, and public accountability would have to exist before any population-scale application could be considered?
04 — Open questions
Questions the evidence could make empirically approachable
Functional capacity and working life
Could functional capacity be measured well enough to inform more flexible arrangements — and what safeguards would prevent such measures being used against the people they are meant to help?
Prevention and health financing
Could measurable improvement help evaluate how prevention is funded — and how would any system avoid disadvantaging people with less capacity to change their trajectory?
Risk assessment: a do-not-use position
Predictive precision can enable discrimination. Biological age should not be used in insurance underwriting or employment decisions, and BioAge Connect’s data governance prohibits those uses.
05 — Governance
Safeguards belong beside the questions they constrain.
Agreed before any sample moves
Data ownership and IP attribution are defined at the outset. Processing aligns with PDPA and IRB requirements. Explicit do-not-use policies cover insurance underwriting and employment decisions. Anti-discrimination safeguards are built into access conditions.
Summary
Fiscally sustainable. Scientifically credible. Genuinely preventive.
Ageing populations create structural pressures that chronological measures cannot resolve because they cannot see the variation that matters. Prevention policy also cannot rest on interventions that have never been tested with endpoints readable in useful time. Both are evidence gaps. Closing them is the work BioAge Connect contributes to.